Interestingly, hypoxia has been shown to downregulate HIPK2 through Siah-2-dependent proteasomal degradation, allowing the induction of a substantial fraction of hypoxia-induced genes [48], therefore, controlling tumor progression and response to therapies. Here, HIPK2 is linked to neoplasm.